
About Nanospectra
Nanospectra is a Technology company based in Houston (United States) founded in 2002. Nanoparticle-based therapies for solid tumor treatment are developed. It operates in the Technology and Healthcare sectors. Nanospectra has raised $24.52 million across 21 funding rounds from investors including HHS, National Cancer Institute and Sirtex. The company has 9 employees. Nanospectra offers products and services including AuroLase Therapy and AuroShells. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is Nanospectra Biosciences, Inc. Its competitors include RefleXion, Sirnaomics and Liquidia; 3 of its 3 listed competitors have raised funding.
Company details
Nanospectra was established in 2002 in Houston, United States, within the biotechnology sector. Particle-based therapies for the thermal ablation of solid tumors, including those in prostate, brain, and breast, are commercialized. AuroLase Therapy, a medical device designed for precise tumor destruction, is offered to address various solid malignancies through selective nanoparticle application. Operations focus on advancing these treatments for clinical use.
- Headquarters Houston, United States
- Employees 9
- SectorsTechnologyHealthcare
- Website nanospectra.com
- Social LinkedIn X
- Legal Name Nanospectra Biosciences, Inc.
- Total Equity Funding$24.52M (USD)
in 21 rounds
- Latest Funding Round$6.07M (USD), Series B
Mar 2023
- InvestorsHHS
& 3 more
- Employee Count9
Products & Services of Nanospectra
Nanospectra offers a comprehensive portfolio of products and services, including AuroLase Therapy and AuroShells.
Uses nanoparticles to selectively destroy tumors via heat.
Gold particles that convert light into heat for medical ablation.
Funding Insights of Nanospectra
Nanospectra has successfully raised a total of $24.52M across 21 strategic funding rounds. The most recent funding activity was a Series B round of $6.07 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.52M
- Total Rounds 21
- Last Round Series B β $6.07M
- First Round $232,800
(Aug 2003)
- Investors Count 4
Latest 10 of 21 funding rounds of Nanospectra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $6.07M | Series B | β | β | β |
| Aug 2020 | $8.61M | Series B | β | Sirtex Medical | β |
| Feb 2017 | $2.03M | Series A | β | β | β |
| Dec 2015 | $945,995 | Seed | β | β | β |
| Aug 2014 | $800,000 | Seed | β | β | β |
| Jun 2013 | $525,000 | Seed | β | β | β |
| Jun 2013 | $2.42M | Seed | β | β | β |
| Nov 2010 | $872,973 | Seed | β | β | β |
| Sep 2010 | $113,665 | Grant | β | β | |
| Sep 2010 | $113,665 | Grant | β | β |
4 investors in total: 4 institutional.
Investors in Nanospectra
Nanospectra has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, National Cancer Institute and Sirtex.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Radiation therapy for cancer treatment is developed and provided. | 1991 | sirtex.com | Sydney, Australia | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Research and information on aging are provided by this institute. | nia.nih.gov | Bethesda, United States |
Investor details for Nanospectra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nanospectra
10 people are tracked at Nanospectra (4 in leadership, 6 in board & advisors); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
David Jorden | CEO & Director | Leadership |
Glenn P. Goodrich | COO & VP, Process Development & Chemistry | Leadership |
Michael Brawer | Chief Medical Officer | Leadership |
Jon Schwartz | Director, Clinical Research | Leadership |
Brian Pryor | Director | Board & advisors |
Patrick W. Pace | Chairman | Board & advisors |
Brad Nyberg | Director | Board & advisors |
L. Blair Shamel | Director | Board & advisors |
Naomi Halas | Advisor | Board & advisors |
Jennifer West | Advisor | Board & advisors |
Complete people profiles for Nanospectra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nanospectra
3 dated milestones of Nanospectra across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Nanospectra is founded.
- Funding First funding round of $233K.
- Funding Latest funding round, Series B, of $6.1M.
Competitors of Nanospectra
Nanospectra has 3 listed competitors in our database, 3 of them funded. They include RefleXion, Sirnaomics and Liquidia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| reflexion.com | 2009 | Hayward, United States | $553.91M | 257 | Biology-guided radiotherapy systems are provided for cancer treatment. | |
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| liquidia.com | 2004 | United States | $75.3M | 63 | Engineered particles & films for life and material sciences applications |
Detailed competitors of Nanospectra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nanotechnology
3 companies that operate in the same segment as Nanospectra (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 34.92 M | 9,630 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nanospectra
Complete news archive for Nanospectra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nanospectra
Nanospectra was founded in 2002 and raised its 1st funding round 1 year after it was founded.
Nanospectra is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Nanospectra is a funded company, having raised a total of $24.52M across 21 funding rounds to date. The company's 1st funding round was a Grant of $113.67K, raised on Aug 2003.
Nanospectra has 9 employees.
Nanospectra was established in 2002 in Houston, United States, within the biotechnology sector. Particle-based therapies for the thermal ablation of solid tumors, including those in prostate, brain, and breast, are commercialized. AuroLase Therapy, a medical device designed for precise tumor destruction, is offered to address various solid malignancies through selective nanoparticle application. Operations focus on advancing these treatments for clinical use.
Nanospectra's top competitors include RefleXion, Sirnaomics and Liquidia.
Nanospectra offers AuroLase Therapy and AuroShells.
Nanospectra has 4 investors. Key investors include HHS, National Cancer Institute, Sirtex, and National Institute on Aging.
Nanospectra operates through Nanospectra Biosciences, Inc..
